SSR240612 [(2 R)-2-[((3 R)-3-(1,3-Benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2 R,6 S)-2,6-dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide Hydrochloride], a New Nonpeptide Antagonist of the Bradykinin B1 Receptor: Biochemical and Pharmacological Characterization
- 1 May 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 309 (2) , 661-669
- https://doi.org/10.1124/jpet.103.059527
Abstract
The biochemical and pharmacological properties of a novel non-peptide antagonist of the bradykinin (BK) B1 receptor, SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-{[(6-methoxy-2-naphthyl)sulfonyl]amino}propanoyl)amino]-3-(4-{[2R,6S)-2,6-dimethylpiperidinyl]methyl}phenyl)-N-isopropyl-N-methylpropanamide hydrochloride] were evaluated. SSR240612 inhibited the binding of [3H]Lys0-des-Arg9-BK to the B1 receptor in human fibroblast MRC5 and to recombinant human B1 receptor expressed in human embryonic kidney cells with inhibition constants (Ki) of 0.48 and 0.73 nM, respectively. The compound selectivity for B1 versus B2 receptors was in the range of 500- to 1000-fold. SSR240612 inhibited Lys0-desAr9-BK (10 nM)-induced inositol monophosphate formation in human fibroblast MRC5, with an IC50 of 1.9 nM. It also antagonized des-Arg9-BK-induced contractions of isolated rabbit aorta and mesenteric plexus of rat ileum with a pA2 of 8.9 and 9.4, respectively. Antagonistic properties of SSR240612 were also demonstrated in vivo. SSR240612 inhibited des-Arg9-BK-induced paw edema in mice (3 and 10 mg/kg p.o. and 0.3 and 1 mg/kg i.p.). Moreover, SSR240612 reduced capsaicin-induced ear edema in mice (0.3, 3 and 30 mg/kg p.o.) and tissue destruction and neutrophil accumulation in the rat intestine following splanchnic artery occlusion/reperfusion (0.3 mg/kg i.v.). The compound also inhibited thermal hyperalgesia induced by UV irradiation (1 and 3 mg/kg p.o.) and the late phase of nociceptive response to formalin in rats (10 and 30 mg/kg p.o.). Finally, SSR240612 (20 and 30 mg/kg p.o.) prevented neuropathic thermal pain induced by sciatic nerve constriction in the rat. In conclusion, SSR240612 is a new, potent, and orally active specific non-peptide bradykinin B1 receptor antagonist.This publication has 28 references indexed in Scilit:
- Interactive contribution of NK1 and kinin receptors to the acute inflammatory oedema observed in response to noxious heat stimulation: studies in NK1 receptor knockout miceBritish Journal of Pharmacology, 2001
- In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCKB receptor antagonist, depends on the dose of systemic morphine and stimulus characteristicsEuropean Journal of Pharmacology, 1997
- Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and micePain, 1997
- Differential action of morphine and various opioid agonists on thermal allodynia and hyperalgesia in mononeuropathic ratsPain, 1994
- SR 140333, a Novel, Selective, and Potent Nonpeptide Antagonist of the NK1 Tachykinin Receptor: Characterization on the U373MG Cell LineJournal of Neurochemistry, 1994
- Induction of bradykinin B1 receptors in vivo in a model of ultra‐violet irradiation‐induced thermal hyperalgesia in the ratBritish Journal of Pharmacology, 1993
- Antinociceptive activity of the bradykinin B1 and B2 receptor antagonists, des-Arg9, [Leu8]-BK and HOE 140, in two models of persistent hyperalgesia in the ratPain, 1993
- Further evidence for ‘pain-related’ behaviours in a model of unilateral peripheral mononeuropathyPain, 1990
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973